The U.S. Food and Drug Administration has extended its review of GSK's LSE:GSK blood cancer drug Blenrep as a combination treatment
https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3TK1KW:0-us-fda-extends-review-of-gsk-s-blood-cancer-drug/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.